BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bartels F, Lu A, Oertel FC, Finke C, Paul F, Chien C. Clinical and neuroimaging findings in MOGAD-MRI and OCT. Clin Exp Immunol 2021. [PMID: 34152000 DOI: 10.1111/cei.13641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Amor S, Nutma E, Owen D. Imaging immune responses in neuroinflammatory diseases. Clin Exp Immunol 2021;206:248-50. [PMID: 34726266 DOI: 10.1111/cei.13670] [Reference Citation Analysis]
2 Seneviratne SO, Marriott M, Ramanathan S, Yeh W, Brilot-Turville F, Butzkueven H, Monif M. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurol 2022;22:84. [PMID: 35264149 DOI: 10.1186/s12883-022-02612-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-chiriboga AS, Pittock SJ, Flanagan EP. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 2022;13:885218. [DOI: 10.3389/fneur.2022.885218] [Reference Citation Analysis]
4 Sánchez P, Chan F, Hardy TA. Tumefactive demyelination: updated perspectives on diagnosis and management. Expert Rev Neurother 2021;21:1005-17. [PMID: 34424129 DOI: 10.1080/14737175.2021.1971077] [Reference Citation Analysis]